Standout Papers
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (2002)
- Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2005)
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2013)
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease (2013)
- Infliximab Maintenance Therapy for Fistulizing Crohn's Disease (2004)
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017)
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial (2012)
- A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis (2006)
- Certolizumab Pegol for the Treatment of Crohn's Disease (2007)
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (2012)
- Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease (2004)
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis (2013)
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis (2011)
- Natalizumab Induction and Maintenance Therapy for Crohn's Disease (2005)
- Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry (2006)
- Methotrexate for the Treatment of Crohn's Disease (1995)
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease (2008)
- Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease (1994)
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry (2012)
- The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016)
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis (2013)
- Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin (2005)
- A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease (2000)
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed (2014)
- A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease (2002)
- C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis (2015)
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2011)
- A Randomized Trial of Arthroscopic Surgery for Osteoarthritis of the Knee (2008)
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis (2016)
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis (2021)
- Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions (2015)
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease (2016)
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017)
- Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review (2019)
- Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023)
- Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study (2022)
Immediate Impact
2 by Nobel laureates 6 from Science/Nature 193 standout
Citing Papers
IL-10 constrains sphingolipid metabolism to limit inflammation
2024 StandoutNature
Crohn's disease
2024 Standout
Works of Brian G. Feagan being referenced
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
2022 Standout
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
2015 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Brian G. Feagan | 40888 | 31094 | 14136 | 14234 | 747 | 52.5k | |
| Paul Rutgeerts | 47645 | 36937 | 16107 | 17665 | 554 | 63.7k | |
| Jean‐Frédéric Colombel | 41043 | 31226 | 15887 | 12563 | 711 | 57.3k | |
| Laurent Peyrin‐Biroulet | 32828 | 24374 | 12865 | 9612 | 1.1k | 47.8k | |
| Séverine Vermeire | 34605 | 25404 | 12297 | 13971 | 1.2k | 53.6k | |
| Geert D’Haens | 30399 | 23520 | 11890 | 8355 | 897 | 41.6k | |
| Bruce E. Sands | 27560 | 20316 | 10502 | 9724 | 579 | 38.2k | |
| Silvio Danese | 28863 | 20178 | 12757 | 12002 | 1.3k | 48.6k | |
| Gert Van Assche | 26295 | 20158 | 10425 | 8740 | 445 | 35.8k | |
| Remo Panaccione | 25603 | 18908 | 9789 | 8003 | 684 | 35.4k | |
| Edward V. Loftus | 25630 | 21033 | 13328 | 4713 | 755 | 36.2k |
All Works
Login with ORCID to disown or claim papers
Loading papers...